in this issue
Markets :: Fine Chemicals/Biotech :: Pharmaceutical ingredients
GlaxoSmithKline licenses Codexis's protein engineering platform
5:13 PM MDT | July 14, 2014 | Rebecca Coons
Biocatalyst firm Codexis (Redwood City, CA) and GlaxoSmithKline (GSK) have announced a license technology agreement worth up to $25 million in initial payments in addition to milestone and royalty opportunities to Codexis. Under the terms of the deal, Codexis granted GSK a license to use Codexis’ proprietary CodeEvolver protein engineering platform technology in the field of human healthcare. The license allows GSK to use Codexis’ platform technology to develop novel enzymes for use in the manufacture of GSK’s pharmaceutical and health...
This information is only available to Chemical Week subscribers.
Forgot your user ID or password?
Not an IHS Chemical Week member yet?
Here's why you should be:
100% Satisfaction Guarantee